Deeper Than the Headlines: Breaking Down a $328 Million Genetic Testing Fraud Scheme

In this episode of Deeper Than the Headlines, we take a closer look at a case that initially sounds like a shocking headline, but reveals far more when examined through a compliance lens.

A former NFL player was found guilty in connection with a genetic testing fraud scheme totaling approximately $328 million. At the center of the case were two laboratories he owned and operated. These labs billed Medicare for genetic tests designed to assess cardiovascular risk, but prosecutors argued the tests were medically unnecessary.

According to case details, the scheme relied heavily on marketers who were allegedly paid kickbacks in exchange for referring Medicare beneficiaries. These payments were structured to appear as marketing fees, yet were reportedly aligned with per-sample referral arrangements, a structure that presents significant Anti-Kickback Statute risk. In total, Medicare paid roughly $54 million before the scheme unraveled.

One of the more troubling aspects described in the case was a tactic referred to as “Doctor Chase.” Marketers allegedly solicited Medicare beneficiaries through telemarketing, obtained their primary care physician information, and then contacted physicians to pressure them into approving genetic testing orders. In some cases, physicians were reportedly told that their patients had already been “qualified” for testing during phone calls. This type of pressure undermines independent medical judgment and places providers in precarious compliance positions.

The individual now faces up to 10 years in prison, with sentencing still pending. Beyond the legal consequences, however, this case underscores broader compliance themes that healthcare organizations cannot afford to ignore.

It highlights the risks of volume-based marketing arrangements, the dangers of insufficient oversight of third-party vendors, and the importance of ensuring that medical necessity is well-documented and defensible. It also serves as a reminder that telemarketing and beneficiary outreach programs, if not carefully structured and monitored, can create significant exposure.

Cases like this are why compliance programs must go beyond policies on paper. Ongoing auditing, careful review of compensation structures, vendor monitoring, and education around red flags are critical safeguards. When incentives become misaligned with patient care, risk escalates quickly.